Physician profile
Nitin Nigam
NPI 1295058790
$1,649.62
in general payments reported to CMS, 2019-2025
15 companies · $284 in 2025
The $284 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $316 · 2020: $88.09 · 2021: $23.87 · 2022: $159 · 2023: $399 · 2024: $380 · 2025: $284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,062.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,062.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $373.94 | 2020-2024 | Eylea, Eylea Hd |
| Allergan, INC. | $274.85 | 2019 | |
| Biotissue Holdings INC. | $236.43 | 2020-2024 | |
| Ocular Therapeutix, INC. | $235.39 | 2024-2025 | Dextenza |
| Genentech USA, INC. | $115.25 | 2023-2025 | Vabysmo |
| Mallinckrodt Hospital Products INC. | $91.87 | 2023-2024 | Acthar |
| Abbvie INC. | $71.36 | 2024-2025 | |
| Astellas Pharma US INC | $56.44 | 2023-2025 | Izervay |
| Alimera Sciences, INC. | $53.37 | 2019-2024 | Iluvien, Yutiq |
| Novartis Pharmaceuticals Corporation | $45.49 | 2019-2020 | |
| Bausch & Lomb Americas INC. | $38.03 | 2023-2025 | Xipere, Visudyne |
| Merz Pharmaceuticals, LLC | $23.87 | 2021 | |
| Biogen, INC. | $19.62 | 2023 | |
| Alcon Vision LLC | $13.71 | 2023 | Eysuvis |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nitin Nigam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.